BioNexus Gene Lab Corp. BGLC
Set alert
0.97 USD -0.04 -3.96%
As of Nov 3, 10:17 AM ET
0.97 Day range 0.98
0.883 52-week range 5.50
- YTD
- -75.44%
- 1 year
- -82.10%
- Open
- 0.97
- Prev close
- 1.01
- Mkt cap
- 2.85M
- Vol
- 8.30K
- Avg vol
- 8.05K
- EPS
- -1.26
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.97
- High
- 0.98
- Forward P/E
- 0.00
- Beta
- 1.87
- Short ratio
- 2.21
- Inst. own
- 0.88%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.31938
- 200-d avg
- 0.470585
- 1y target
- 0.00
5D chart
Signals (32)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2:15 PM | 20 hours ago |
| MACD: Sell Signal | Nov 2, 1:40 PM | 21 hours ago |
| MACD: Buy Signal | Nov 2, 1:30 PM | 21 hours ago |
| MACD: Sell Signal | Nov 2, 1:25 PM | 21 hours ago |
| MACD: Buy Signal | Nov 2, 11:50 AM | 23 hours ago |
| MACD: Sell Signal | Nov 2, 10:40 AM | 1 day ago |
| SMA: Bullish | Nov 2, 10:30 AM | 1 day ago |
| SMA: Bearish | Nov 2, 10:20 AM | 1 day ago |
| RSI: Overbought | Nov 2, 9:30 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 4 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 30, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 4 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 3:55 PM | 4 days ago |
| RSI: Oversold | Oct 29, 3:55 PM | 4 days ago |
Newest 20 of 32.
Financial health
Altman Z-Score
0.33 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 5
- P/E 1
- P/B 5
Valuation
P/E -2.5×
FY 2016 5y median -3.1× FY 2025
P/S 1.0×
FY 2016 5y median 1.0× FY 2025
P/B 0.9×
FY 2016 5y median 0.9× FY 2025
P/FCF -3.9×
FY 2016 5y median -2.0× FY 2025
EV/EBITDA -1.8×
FY 2016 5y median -1.3× FY 2025
EV/Sales 0.7×
FY 2016 5y median 0.7× FY 2025
FCF Yield -25.6%
FY 2016 5y median -20.9% FY 2025
Profitability
Gross Margin 14.6%
FY 2016 5y median 13.6% FY 2025
Operating Margin -42.5%
FY 2016 5y median -16.5% FY 2025
Net Margin -40.2%
FY 2016 5y median -16.8% FY 2025
ROE -34.6%
FY 2016 5y median -19.2% FY 2025
ROIC -35.9%
FY 2016 5y median -18.4% FY 2025
ROA -32.3%
FY 2016 5y median -15.3% FY 2025
Growth (YoY)
Revenue -21.9%
FY 2016 FY 2025
Operating Income -100.7%
FY 2016 FY 2025
EPS (diluted) -78.9%
FY 2016 FY 2025
Free Cash Flow 23.8%
FY 2016 FY 2025
Financial Health
Current Ratio 10.5×
FY 2016 5y median 3.8× FY 2025
Quick Ratio 9.2×
FY 2016 5y median 3.1× FY 2025
Debt / Equity 0.0×
FY 2016 5y median 0.0× FY 2025
Net Debt / EBITDA 0.8×
FY 2016 5y median 2.3× FY 2025
Interest Coverage -162×
FY 2016 5y median -74.4× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
